Abstract
This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.
Original language | English |
---|---|
Pages (from-to) | e105-e118 |
Journal | The Lancet Oncology |
Volume | 22 |
Issue number | 3 |
DOIs | |
Publication status | Published - Mar 2021 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Lancet Oncology, Vol. 22, No. 3, 03.2021, p. e105-e118.
Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - Treatment of relapsed and refractory multiple myeloma
T2 - recommendations from the International Myeloma Working Group
AU - Moreau, Philippe
AU - Kumar, Shaji K.
AU - San Miguel, Jesús
AU - Davies, Faith
AU - Zamagni, Elena
AU - Bahlis, Nizar
AU - Ludwig, Heinz
AU - Mikhael, Joseph
AU - Terpos, Evangelos
AU - Schjesvold, Fredrik
AU - Martin, Thomas
AU - Yong, Kwee
AU - Durie, Brian G.M.
AU - Facon, Thierry
AU - Jurczyszyn, Artur
AU - Sidana, Surbhi
AU - Raje, Noopur
AU - van de Donk, Niels
AU - Lonial, Sagar
AU - Cavo, Michele
AU - Kristinsson, Sigurdur Y.
AU - Lentzsch, Suzanne
AU - Hajek, Roman
AU - Anderson, Kenneth C.
AU - João, Cristina
AU - Einsele, Hermann
AU - Sonneveld, Pieter
AU - Engelhardt, Monika
AU - Fonseca, Rafael
AU - Vangsted, Annette
AU - Weisel, Katja
AU - Baz, Rachid
AU - Hungria, Vania
AU - Berdeja, Jesus G.
AU - Leal da Costa, Fernando
AU - Maiolino, Angelo
AU - Waage, Anders
AU - Vesole, David H.
AU - Ocio, Enrique M.
AU - Quach, Hang
AU - Driessen, Christoph
AU - Bladé, Joan
AU - Leleu, Xavier
AU - Riva, Eloisa
AU - Bergsagel, Peter Leif
AU - Hou, Jian
AU - Chng, Wee Joo
AU - Mellqvist, Ulf Henrik
AU - Dytfeld, Dominik
AU - Harousseau, Jean Luc
AU - Goldschmidt, Hartmut
AU - Laubach, Jacob
AU - Munshi, Nikhil C.
AU - Gay, Francesca
AU - Beksac, Meral
AU - Costa, Luciano J.
AU - Kaiser, Martin
AU - Hari, Parameswaran
AU - Boccadoro, Mario
AU - Usmani, Saad Z.
AU - Zweegman, Sonja
AU - Holstein, Sarah
AU - Sezer, Orhan
AU - Harrison, Simon
AU - Nahi, Hareth
AU - Cook, Gordon
AU - Mateos, Maria Victoria
AU - Rajkumar, S. Vincent
AU - Dimopoulos, Meletios A.
AU - Richardson, Paul G.
N1 - Funding Information: PM reports honoraria from Amgen, Celgene, Janssen, AbbVie, and Sanofi; and participation in advisory boards for Amgen, Celgene, Janssen, AbbVie, and Sanofi. SKK reports research grants from AbbVie, Celgene, Janssen, Takeda, Adaptive, Kite, Medimmune (AstraZeneca), Merck Sharp and Dohme, Novartis, Roche, Sanofi, and Oncopeptides; and participation in the advisory boards of and research support for clinical trials paid to institution from AbbVie, Celgene, Janssen, Takeda, Adaptive, Kite, Medimmune (AstraZeneca), and Oncopeptides. JSM reports participation in advisory boards for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck Sharp and Dohme, Novartis, Takeda, Roche, Sanofi, GlaxoSmithKline, AbbVie, and Karyopharm. FD reports research grants from Janssen and Celgene; honoraria from Adaptive Biotech, Janssen, Celgene, Takeda, Sanofi, Oncopeptide, and Roche; and participation in advisory boards for Adaptive Biotech, Janssen, Celgene, Takeda, Sanofi, Oncopeptide, and Roche. NB reports research grants from Celgene; and honoraria from Janssen, AbbVie, Sanofi, Genentech, Amgen, Karyopharm, and Pfizer. HL reports research funding from Takeda and Amgen; and honoraria from Takeda, Amgen, Sanofi, Janssen, and Celgene. JM reports honoraria from Amgen, Bristol-Myers Squibb, Janssen, Karyopharm, Sanofi, and Takeda. ET reports research grants from Janssen, Amgen, Celgene, Genesis Pharma, and Sanofi; honoraria from Janssen, Takeda, Amgen, Celgene, Genesis Pharma, Sanofi, Bristol-Myers Squibb, and Novartis; and non-financial support from Takeda, Amgen, Celgene, and Genesis Pharma. FS reports research grants from Amgen, Celgene, Oncopeptides, Sanofi, and GlaxoSmithKline; and honoraria from Amgen, Celgene, Takeda, Janssen, Novartis, SlyliteDX, Oncopeptides, Sanofi, GlaxoSmithKline, and Merck Sharp and Dohme. TM reports research support paid to institution from Sanofi, Amgen, Janssen, and Seattle Genetics; and consulting for Roche and GlaxoSmithKline. KY reports research grants from Sanofi and Janssen; and honoraria from Takeda. TF reports honoraria from Janssen, Bristol-Myers Squibb, Takeda, Amgen, Sanofi, Roche, Oncopeptides, and Karyopharm. SS reports research grants from Magenta Therapeutics and honoraria from Janssen. NR reports research grants from Blue Bird Bio; and honoraria from Bristol-Myers Squibb, Amgen, Janssen, Takeda, AstraZeneca, Oncopeptide, Immuneel, and Caribou Biosciences. NvdD reports research grants from Janssen Pharmaceuticals, Amgen, Celgene, Novartis, and Bristol-Myers Squibb. SLo reports honoraria from Celgene, Bristol-Myers Squibb, Janssen, Takeda, Novartis, GlaxoSmithKline, AbbVie, and Karyopharm. MC reports honoraria from Janssen, Celgene, Bristol-Myers Squibb, Sanofi, GlaxoSmithKline, and Mundipharma. SLe reports research grants from Sanofi and Karyopharm; and honoraria from Sorrento, Janssen, Cellularity, Caelum, Takeda, Adaptive, GlaxoSmithKline, Sanofi, AbbVie, Bayer, Amgen, and Proclara. RH reports research grants from Takeda and Novartis; and honoraria from Janssen, Amgen, Celgene, AbbVie, Bristol-Myers Squibb, Pharmamar, Takeda, and Novartis. KCA reports honoraria from Bristol-Myers Squibb, Millenium Pharmaceuticals, Gilead, Sanofi, Amgen, and Precision Biosciences; and is a scientific founder of C4 therapeutics and Oncopep. CJ reports research grants from Takeda; and honoraria from Takeda, Janssen, Celgene, and Amgen. HE reports research grants from Celgene, Janssen, Amgen, Sanofi, and GlaxoSmithKline; and honoraria from Celgene, Janssen, Amgen, Takeda, Sanofi, and GlaxoSmithKline. PS reports research grants from Amgen, Celgene, Janssen, Karyopharm, SkylineDX, and Takeda; and honoraria from Amgen, Celgene, Janssen, Karyopharm, SkylineDX, and Takeda. ME reports research grants from Amgen, Janssen, Takeda, and Bristol-Myers Squibb. RF reports being a consultant for Merck Sharp and Dohme, Novartis, Oncotracker, Pharmacyclics, GlaxoSmithKline, Janssen, Sanofi, Takeda, and Oncopeptides; and has a FISH patent with royalties paid. KW reports research grants from Amgen, Celgene, Janssen, and Sanofi; and honoraria from Amgen, Celgene, Bristol-Myers Squibb, Adaptive Biotech, Janssen, GlaxoSmithKline, Karyopharm, Sanofi, Takeda, and Oncopeptides. RB reports research grants from Janssen, Bristol-Myers Squibb, Karyopharm, Sanofi, and AbbVie; and honoraria from Janssen, Celgene, Karyopharm, Sanofi, and GlaxoSmithKline. VH reports honoraria from AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Sanofi, and Takeda. JGB reports research grants from Vivolux, AbbVie, Amgen, Acetylon, Bluebird, Bristol-Myers Squibb, Celgene, Cellularity, Constellation, CRISPR Therapeutics, CURIS, EMD Sorono, GenentechInc, Glenmark, Janssen, Kesios, Lilly, Novartis, Poseida, Teva, and Takeda; and being a consultant for Amgen, Bioclinica, Bristol-Myers Squibb, Celgene, CRISPR Therapeutics, Janssen, Karyopharm, Kite Pharma, Legend, Prothena, Servier, Takeda, Bluebird, and SecuraBio. FLdC reports honoraria from Amgen, Takeda, Janssen, Viforpharma, and Celgene. AM reports honoraria from Janssen, Takeda, Amgen, Bristol-Myers Squibb, and Sanofi. AW reports research grants from Takeda and honoraria from Janssen. DHV reports honoraria from Amgen, Takeda, Janssen, GlaxoSmithKline, Karyopharm, and Bristol-Myers Squibb. EMO reports honoraria from Celgene, Janssen, Sanofi, Amgen, Merck Sharp and Dohme, Asofarma, Takeda, SecuraBio, Oncopeptides, and GlaxoSmithKline. HQ reports research grants from GlaxoSmithKline, Amgen, Karyopharm, and Celgene; and honoraria from GlaxoSmithKline, Amgen, and Karyopharm. JB reports honoraria from Janssen, Celgene, Amgen, Takeda, and Oncopeptides. PLB reports honoraria from Celgene, Janssen, GlaxoSmithKline, and Novartis. JH reports research grants from the National Natural Science Foundation of China and honoraria from Janssen. U-HM reports honoraria from Janssen, Sanofi, Amgen, Celgene, and Oncopeptides. DD reports research grants from Celgene and Janssen; and honoraria from Amgen, Celgene, Janssen, and Takeda. J-LH reports honoraria from GlaxoSmithKline, Daichi, and Janssen. HG reports research grants from Bristol-Myers Squibb, Celgene, Janssen, Chugai, Sanofi, Takeda, Novartis, Incyte, Molecular Partners, Mundipharma, and Adaptive Technologies; and honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Chugai, Sanofi, Novartis, and GlaxoSmithKline. NCM reports honoraria from AbbVie, Adaptive, Amgen, BeiGene, Bristol-Myers Squibb, Celgene, Janssen, Karyopharm, Takeda, and Oncopep. FG reports honoraria from Amgen, Celgene, Janssen, Takeda, Bristol-Myers Squibb, Roche, AbbVie, Adaptive Biotechnologies, Seattle Genetics, Oncopeptides, and GlaxoSmithKline. MBe reports participation in advisory boards for Amgen, Bristol-Myers Squibb, Janssen, Sanofi, Takeda, and Oncopeptides. LJC reports research grants from Amgen and Janssen; and honoraria from Amgen, Janssen, Genentech, AstraZeneca, and Bristol-Myers Squibb. MK reports research grants from Janssen and honoraria from Amgen, AbbVie, Celgene, GlaxoSmithKline, Janssen, Karyopharm, and Takeda. PH reports research grants from Celgene, Takeda, Janssen, GlaxoSmithKline, and Sanofi; and honoraria from Celgene, Takeda, Amgen, Karyopharm, Janssen, GlaxoSmithKline, and Sanofi. MBo reports research grants from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma; and honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, AbbVie, and GlaxoSmithKline. SZU reports research grants from Amgen, Bristol-Myers Squibb, Celgene, Pharmacyclics, Sanofi, Seattle Genetics, Janssen, Takeda, SkylineDX, and Merck Sharp and Dohme; and honoraria from Amgen, AbbVie, Celgene, Mundipharma, Sanofi, Seattle Genetics, Janssen, Takeda, SkylineDX, and Merck Sharp and Dohme. SZ reports research grants from Janssen and Takeda; and being a consultant for Janssen, Takeda, Bristol-Myers Squibb, Sanofi, and Oncopeptides. SHo reports research grants from Oncopeptides; and honoraria from Celgene, GlaxoSmithKline, Oncopeptides, Sorrento, Sanofi, Genentech, and Takeda. SHa reports research grants from Bristol-Myers Squib, Celgene, Janssen, and Amgen; and honoraria from Bristol-Myers Squib, Celgene, Janssen, Amgen, Takeda, GlaxoSmithKline, AbbVie, and Karyopharm. GC reports research grants from Takeda, Celgene, and Janssen; and honoraria from Takeda, Celgene, Janssen, and Karyopharm. M-VM reports honoraria from Janssen, Bristol-Myers Squib, Amgen, Takeda, GlaxoSmithKline, AbbVie, Adaptive, Pfizer, Genentech, Roche, Oncopeptides, and Sanofi. MAD reports honoraria from Amgen, Bristol-Myers Squib, Janssen, Takeda, and Beigene. PGR reports research grants from Bristol-Myers Squib, Oncopeptides, Celgene, Takeda; and honoraria from Oncopeptides, Celgene, Takeda, Karyopharm, Janssen, Sanofi, and SecuraBio. All other authors declare no competing interests. Publisher Copyright: © 2021 Elsevier Ltd
PY - 2021/3
Y1 - 2021/3
N2 - This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.
AB - This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85101689680&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/S1470-2045(20)30756-7
DO - https://doi.org/10.1016/S1470-2045(20)30756-7
M3 - Review article
C2 - 33662288
SN - 1470-2045
VL - 22
SP - e105-e118
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 3
ER -